Protracted review period for Exubera

Share this article:
The FDA notified Pfizer and Sanofi-Aventis that it is extending the original review period for Exubera, the companies' experimental inhaled insulin product, by three months.
The period is being prolonged "to review additional technical chemistry data submitted by the companies," the firms said today in a statement.
The PDUFA (Prescription Drug User Fee Act) date of Oct. 27 has been changed to Jan. 27.
In September the FDA's Endocrinologic & Metabolic Drugs Advisory Committee voted 7-2 in favor of approving Exubera, which Pfizer and Sanofi-Aventis are developing with Nektar Therapeutics, despite concerns about potential adverse lung effects.
Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...